Related references
Note: Only part of the references are listed.Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis
Ts-Ting Lin et al.
JOURNAL OF CONTROLLED RELEASE (2016)
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer
Dong-Yu Gao et al.
BIOMATERIALS (2015)
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer
Keiichi Ota et al.
CLINICAL CANCER RESEARCH (2015)
CXCR4 Inhibition in Tumor Microenvironment Facilitates Anti-Programmed Death Receptor-1 Immunotherapy in Sorafenib-Treated Hepatocellular Carcinoma in Mice
Yunching Chen et al.
HEPATOLOGY (2015)
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis
Thomas Reiberger et al.
NATURE PROTOCOLS (2015)
Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma - an auto-commentary on clinical potential and future development
Yunching Chen et al.
ONCOIMMUNOLOGY (2015)
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
Ho Yeong Lim et al.
CLINICAL CANCER RESEARCH (2014)
Differential Effects of Sorafenib on Liver Versus Tumor Fibrosis Mediated by Stromal-Derived Factor 1 Alpha/C-X-C Receptor Type 4 Axis and Myeloid Differentiation Antigen-Positive Myeloid Cell Infiltration in Mice
Yunching Chen et al.
HEPATOLOGY (2014)
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Ramona Rudalska et al.
NATURE MEDICINE (2014)
Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis
Donald Wong et al.
BMC UROLOGY (2014)
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients
L. Boussemart et al.
ANNALS OF ONCOLOGY (2013)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
A Proposal Regarding Reporting of In Vitro Testing Results
Malcolm A. Smith et al.
CLINICAL CANCER RESEARCH (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcala et al.
CLINICAL CANCER RESEARCH (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bim Protein Degradation Contributes to Cisplatin Resistance
Juan Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
HCC and angiogenesis: possible targets and future directions
Andrew X. Zhu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Mst1 and Mst2 Maintain Hepatocyte Quiescence and Suppress Hepatocellular Carcinoma Development through Inactivation of the Yap1 Oncogene
Dawang Zhou et al.
CANCER CELL (2009)
Tumour cell survival signalling by the ERK1/2 pathway
K. Balmanno et al.
CELL DEATH AND DIFFERENTIATION (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Hepatocellular carcinoma pathogenesis: from genes to environment
Paraskevi A. Farazi et al.
NATURE REVIEWS CANCER (2006)
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy
TT Tan et al.
CANCER CELL (2005)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
